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OBJECTIVEdTo delineate the associations of total adiponectin, high-molecular-weight
(HMW) adiponectin, and the HMW-to-total adiponectin ratio with diabetes in older adults.
RESEARCH DESIGN AND METHODSdTotal and HMW adiponectin were measured
in a population-based study of older adults. The relations of total adiponectin, HMW adiponectin,
and their ratio with incident diabetes (n = 309) were assessed in 3,802 individuals.
RESULTSdTotal and HMW adiponectin were highly correlated (r = 0.94). Analysis using
cubic splines revealed that the associations between total and HMW adiponectin and new-onset
diabeteswerenotlinear.Speciﬁcally,afteradjustmentforconfounders,thereweresimilarinverse
relationships for total (hazard ratio per SD 0.49 [95% CI 0.39–0.63]) and HMW adiponectin
(0.42 [0.32–0.56]) with diabetes up to values of 20 and 10 mg/L, respectively, above which the
associations plateaued. These associations persisted after adjustment for potential mediators
(blood pressure, lipids, C-reactive protein, and homeostasis model assessment of insulin resis-
tance[HOMA-IR]).Therewas,however,evidenceof interactionbyHOMA-IR inthelowerrange
of adiponectin, with stronger inverse associations among insulin-sensitive than insulin-resistant
participants. HMW-to-total adiponectin ratio showed a linear adjusted association with out-
come, but this was abolished by inclusion of mediating variables.
CONCLUSIONSdInthisoldercohort,increasingconcentrationsoftotalandHMWadiponectin
were associated with comparably lower risks of diabetes, but these associations leveled off with
further increases above concentrations of 20 and 10 mg/L, respectively. The more pronounced risk
decreases at the lower range among participants without insulin resistance support a role for adi-
ponectinthatisindependentofbaselinehyperinsulinemia,butthiswillrequirefurtherinvestigation.
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T
he widening epidemic of type 2 di-
abetes poses a major challenge to the
public health (1). Although the in-
creasing burden of diabetes in the U.S.
has been borne by adults in all age cate-
gories, the greatest share has fallen upon
the older segment, with nearly one-third
ofadultsaged$65yearsaffected(1,2).As
in younger age groups, the prevalence of
dysglycemia in elders has risen in tandem
with excess adiposity, yet the proportion
of older adults with diabetes who are
overweight or obese is more modest (3).
This has led to the concept that diabetes
in older adults may have different patho-
physiologic features, with a greater role
for impaired pancreatic insulin secretion
relative to the obesity-associated insulin
resistance that predominates in diabetes
occurring earlier in life (3).
Still, the prevailing link between ad-
iposity and diabetes across the age spec-
trum has focused attention on the role
of various bioactive peptides secreted
by adipocytes as potential mediators of
obesity-associated dysglycemia (4). Of
these adipokines, adiponectin circulates
inconcentrationsthreeordersofmagnitude
greater than any other, although plasma
levels of adiponectin exhibit a paradoxic
decline with increasing adiposity (5). In
animal models, elimination of adiponectin
production leads to insulin resistance,
whereas repletion of adiponectin restores
insulin sensitivity (6). Acting through
cognate receptors, adiponectin stimu-
lates AMP-activated protein kinase and
peroxisome-proliferator activated receptor-
a (PPAR-a) to promote fatty acid catabo-
lism andenhance insulinsensitivity inthe
liver and skeletal muscle (6). The stron-
gest insulin-sensitizing actions appear to
reside with the high-molecular-weight
(HMW) fraction of adiponectin, which
increases preferentially in response to
PPAR-g agonists and may mediate the
insulin-sensitizingeffectsoftheseagents
(7). Yet adiponectin also inﬂuences the
function of pancreatic b-cells, and its an-
tiapoptoticactionsonsuchcellscouldcon-
tribute to its favorable glycometabolic
properties (8).
Consistent with preclinical investiga-
tions, a meta-analysis of prospective ep-
idemiologic studies demonstrated an
inverse association between total circulat-
ing adiponectin levels and incident diabe-
tes(9).Thissystematicreviewreportedthat
the association tended to be stronger for
younger than older adults, based principally
on two published studies (10,11) focusing
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ORIGINAL ARTICLEon older people, although effect-measure
modiﬁcation by age was not signiﬁcant.
Fewerprospectivestudies(12–14)haveeval-
uated the association for HMW adiponectin,
documentingsimilarprotectiveassociations
asfortotaladiponectin,butnostudytodate
has addressed this question longitudinally
inanolderpopulation.Wesoughttoexam-
ine in detail the relative associations of
HMWandtotaladiponectin,aswellastheir
ratio (7), with diabetes incidence in a pro-
spective cohort of older adults, in order to
determine the extent to which ﬁndings
from middle-aged cohorts apply to older
individuals.
RESEARCH DESIGN AND
METHODS
Study population
The Cardiovascular Health Study (CHS)
is a population-based investigation of
cardiovascular disease (CVD) and its de-
terminants in older adults. As reported
previously (15), participants consisted
of community-dwelling individuals aged
65 years and older identiﬁed from Medi-
care eligibility lists. Enrollment occurred
at four U.S. ﬁeld centers in California,
Maryland, North Carolina, and Pennsyl-
vania. An original cohort (n = 5,201) was
r e c r u i t e di n1 9 8 9 –1990, followed in
1992–1993 by a supplemental cohort of
African Americans (n = 687). Standard-
ized health evaluations of participants
were performed at site clinics using pre-
viously described protocols (15,16).
The 1992–1993 examination in-
cluded 5,553 returning or newly added
individuals, of whom 4,715 had samples
available for adiponectin measurement.
For the present analyses, we excluded
708 participants with prevalent diabetes,
and 205 with missing data for determina-
tion of baseline or incident diabetes sta-
tus, leaving 3,802 eligible individuals.
Ascertainment and deﬁnition
of diabetes
Glucose was measured in blood samples
(17) collected in 1989–1990, 1992–1993,
1994–1995, 1996–1997, 1998–1999, and
2005–2006. All visits except for 1994–
1995 stipulated a prior overnight fast, and
all measurements were in serum except for
1998–1999, which used EDTA-plasma.
Time since last intake of food or drink
was obtained by questionnaire at all visits.
An inventory of medication use was com-
piled at baseline and annually thereafter
(18). Prevalent and incident diabetes was
deﬁned by 1)g l u c o s e$126 mg/dL when
participants had reported fasting $8 h be-
forevenipuncture;2)gl uc os e$200mg/dL
when last oral intake was ,8 h from veni-
puncture; or 3) use of hypoglycemic med-
ication. Prediabetes was deﬁned by fasting
blood glucose of 100–125 mg/dL or non-
fasting blood glucose of 140–199 mg/dL.
Risk factor deﬁnitions
Hypertension was deﬁned by systolic and
diastolic blood pressure cutoffs of 140 and
9 0m m H go rb ys e l f - r e p o r ta n da n t i h y -
pertensive therapy.Anthropometricmeas-
urements were performed in standardized
fashion by trained personnel, as reported
elsewhere (19). Leisure-time physical activ-
itywascalculatedasaweightedsumofkilo-
calories expended in speciﬁcp h y s i c a l
tasks (20). Prevalent CVD included coro-
nary heart disease (CHD), heart failure,
atrialﬁbrillation,stroke,transientischemic
attack, and peripheral arterial disease, as-
certained at the 1989–1990 and 1992–
1993 examinations by combining the
CHS questionnaire, medical-record re-
view, and physician conﬁrmation (16).
Additional laboratory measurements
onfastingbaselinesamples(17)included
creatinine, lipids, insulin, and high-
sensitivity C-reactive protein (hsCRP)
(21). The homeostasis model assessment
ofinsulinresistance(HOMA-IR)indexwas
calculated as fasting insulin (mU/mL) 3
fastingglucose(mmol/L)/22.5(22).Thees-
timated glomerular ﬁltration rate (eGFR)
was calculated using the Modiﬁcation of
Diet in Renal Disease equation (23).
Measurement of glucose and
harmonization procedures
All CHS glucose assayswere performed at
the University of Vermont Central Blood
Analysis Laboratory.G l u c o s ew a sa n a -
lyzed using enzymatic methods with an-
alytical coefﬁcients of variation (CVs)
under2%.Samplesfrommajorexamyears
(1989–1990, 1992–1993, and 1996–
1997) along with samples from 2005–
2006,wereanalyzedshortlyaftercollection
usingtheKodakEktachem700(Eastman
Kodak,Rochester,NY)(17)ortheJohnson
& Johnson Vitros 950 IRC (Johnson &
Johnson Clinical Diagnostics, Rochester,
NY). Samples from other years were ana-
lyzed in 2010 using the Roche Integra
400 (Roche Diagnostics, Indianapolis,
IN).
To minimize measurement error and
misclassiﬁcation of participants that can
resultfromdifferencesinglucosemeasure-
ment over time, we harmonized measure-
ments performed before 2010 with those
obtained contemporaneously. This was
accomplished by selecting a subset of 48
participants who had specimens available
from all previous examinations and reas-
saying their samples in 2010 with the
Rocheinstrument.Additionally,toidentify
any differences in glucose measurements
attributable to plasma, glucose was mea-
sured in 48 samples of serum and plasma
from stored specimens in 1996–1997,
when both specimen types were available.
We then compared the new glucose mea-
surements with the original ones among
the subset of participants with paired mea-
surementsbyevaluatingcorrelationcoef-
ﬁcients, regression lines, Bland-Altman
plots, and mean differences. In all years,
the correlation between the original and
newassayswashigh(0.91–0.99),andthere
was no statistical evidence of a multiplica-
tive effect (regression slopes did not differ
from1).Thereweredifferencesinthemean
values,however,andadjustmentswereun-
dertaken based on these mean differences
to align all glucose measurements to those
from 1989–1990. Harmonized glucose
measurements were used for all analyses,
including ascertainment of prediabetes
and diabetes.
Measurement of adiponectin
Measurements of adiponectin were per-
formed on EDTA-plasma samples stored
at 2708C since collection. Total and
HMW adiponectin were measured using
an enzyme-linked immunosorbent assay
(Millipore, Billerica, MA); interassay analyt-
icalCVswere6.9%and11.1%,respectively.
Statistical analysis
Correlations between adiponectin and
baseline covariates were assessed by com-
puting Pearson coefﬁcients after natural
log transformation of highly skewed var-
iables.Differencesinadiponectinconcen-
trations by levels of categorical variables
were evaluated with the Student t test or
ANOVA. The functional forms of the as-
sociationsoftotaladiponectin,HMWadi-
ponectin, and HMW-to-total adiponectin
ratio with incident diabetes were exam-
ined using general additive model plots,
with the measure of interest ﬁtu s i n ga
penalized cubic spline. Nonlinearity of
associations was tested with the gain sta-
tistic, which compares the difference in
normalized deviance between the cubic
spline model and a model ﬁt with a linear
termforthepredictorofinterest(24).Con-
tinuous associations of total adiponectin
and HMW adiponectin with incident dia-
betes were modeled using linear splines
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Adiponectin and diabetes in older peoplewith knots chosen at 20 and 10 mg/L, re-
spectively, based on visual inspection of
general additive model plots and, forto-
tal adiponectin, also the association with
death observed previously in a follow-up
study involving this cohort (25).
Associationsofquartilesofeachadipo-
nectin measure with outcome were also
evaluated. Although mean adiponectin
levels were signiﬁcantly higher in women
than in men,there was substantialoverlap
in values. Because there was no evidence
of interaction by sex (P = 0.20) in the re-
lation of total or HMW adiponectin with
outcome, we examined overall quartiles
rather than sex-speciﬁc quartiles. Cox
proportional hazards models were used
to evaluate associations with time to inci-
dent diabetes. The proportional hazards
assumption was tested by the Schoenfeld
goodness-of-ﬁtprocedures,whichdidnot
reveal meaningful violations.
Models were adjusted for age, sex, and
race, as well as for potential confounders,
wherein covariates that were found to ma-
terially inﬂuence the risk estimate (.10%
change) wereretained. Subsequent models
consideredtheeffectofputativemediators,
namely, systolic blood pressure, HDL cho-
lesterol, triglycerides, hsCRP, HOMA-IR,
andfastingglucose. Toevaluateforinterac-
tions with sex, age, race, BMI, and HOMA-
IR, appropriate cross-product terms were
included.Thiswasperformedbyexcluding
adiponectin outliers at the upper tail (ex-
treme 2.5% of values) and by considering
covariates both continuously and dichoto-
mized by their median (age and BMI) or
75th percentile (HOMA-IR, to deﬁne insu-
lin resistance). Owing to the detection of
nonlinear relationships for both total and
HMW adiponectin, cross-product terms
wereincludedforadiponectinvaluesbelow
and above the observed inﬂection points.
Signiﬁcance was assessed separately for
each cross-product term (Wald test), as
well as overall for the multivariable model
with both cross-product terms versus nei-
ther (likelihood ratio test).
We did not examine total and HMW
adiponectin jointly in multivariable mod-
els because the two measures were very
highly correlated (r =0 . 9 4o r0 . 8 9w h e n
log-transformed), which would render
their mutually adjusted regression coefﬁ-
cients uninterpretable. Last, we conduc-
tedsensitivity analysesfocusing onevents
occurring .5 years of follow-up or based
on antidiabetes medication use only, or
that excluded participants with uninten-
tional weight loss .10 lb in the previous
year or with prevalent CHD, heart failure,
andatrialﬁbrillation.Allanalyseswereper-
formed with STATA 11.0 software (Stata-
Corp LP, College Station, TX).
RESULTSdParticipants with adiponec-
tin measurements included more women
and African Americans, and were younger
and in better health, than those without
such measurements, consistent with spec-
imen depletionformembersoftheoriginal
cohort with early CVD events. The mean
age of the study sample was 74.8 6 5.2
years, of which 63.3% were women. Total
and HMW adiponectin distributions were
positively skewed, with geometric means
(95% CIs) of 12.8 mg/L (12.6–13.0) and
6.2 mg/L (6.0–6.3), respectively, whereas
HMW-to-total adiponectin ratio was nor-
mally distributed (0.51 [0.50–0.52]).
Total and HMW adiponectin were
highly correlated, as reported in Table 1.
Moderate positive correlations were ob-
servedfortotaladiponectin,HMWadipo-
nectin, and HMW-to-total adiponectin
ratio each with age and HDL cholesterol,
as were marginal correlations with sys-
tolic blood pressure (Table 1). Moderate
negative correlations were in turn pres-
ent for both total adiponectin and HMW
adiponectin (and their ratio) with BMI,
waist-to-hip ratio, triglycerides, hsCRP,
fasting glucose, fasting insulin, and
HOMA-IR, with weaker negative corre-
lations observed with diastolic blood
pressure.
Table 2 presents values of total adi-
ponectin,HMWadiponectin,andHMW-
to-total adiponectin ratio according to so-
ciodemographic and clinical subgroups.
Higher values of all three adiponectin
measures were observed in women, par-
ticularly those receiving estrogen replace-
menttherapy,aswellasinparticipantsof
nonblack ethnicity; in individuals from
theCaliforniaandMarylandﬁeldcenters;
in participants with greater alcohol in-
take; and in those who never smoked,
had normalfastingglucose,orexperienced
.10-lb unintentional weight loss in the
past year (only HMW adiponectin and
HMW-to-total adiponectin ratio). In
turn, participants with prevalent heart
failure or atrial ﬁbrillation had greater
levels of all adiponectin measures, while
those with CHD or using b-blockers ex-
hibited lower concentrations.
During a median follow-up of 10.6
(maximum, 14.9) years, 309 cases of inci-
dentdiabetesoccurred.Inspectionofcubic
spline plots, with or without adjustment
forpotentialconfounding,revealedthatto-
tal and HMW adiponectin were inversely
associated with incident diabetes up to
circulating concentrations of ;20 mg/L
(;80th percentile) and ;10 mg/L (;75th
percentile), respectively, above which
such associations plateaued (P , 0.001
for nonlinearity for both; Fig. 1). By con-
trast, spline plots showed that the associ-
ation of HMW-to-total adiponectin ratio
Table 1dCorrelations between adiponectin and baseline covariates
Covariate
Log(total
adiponectin)
Log(HMW
adiponectin)
HMW-to-total
adiponectin ratio
rPrPr P
Age 0.204 ,0.001 0.181 ,0.001 0.110 ,0.001
BMI 20.297 ,0.001 20.267 ,0.001 20.149 ,0.001
Waist-to-hip ratio 20.335 ,0.001 20.299 ,0.001 20.171 ,0.001
Physical activity index 20.056 0.001 20.046 0.007 20.040 0.02
Systolic blood pressure 0.026 0.11 0.025 0.13 0.025 0.12
Diastolic blood pressure 20.072 ,0.001 20.067 ,0.001 20.034 0.03
LDL cholesterol 20.010 0.56 0.003 0.84 0.012 0.47
HDL cholesterol 0.479 ,0.001 0.415 ,0.001 0.218 ,0.001
Log(triglycerides) 20.305 ,0.001 20.258 ,0.001 20.142 ,0.001
eGFR 20.031 0.06 20.001 0.97 0.046 0.005
Log(hsCRP) 20.212 ,0.001 20.165 ,0.001 20.062 ,0.001
Fasting glucose 20.231 ,0.001 20.213 ,0.001 20.118 ,0.001
Fasting insulin 20.270 ,0.001 20.245 ,0.001 20.141 ,0.001
Log(HOMA-IR) 20.414 ,0.001 20.378 ,0.001 20.219 ,0.001
Log(total adiponectin) dd 0.888 ,0.001 0.429 ,0.001
Log(HMW adiponectin) 0.888 ,0.001 dd0.696 ,0.001
HMW-to-total
adiponectin ratio 0.429 ,0.001 0.696 ,0.001 dd
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Kizer and AssociatesTable 2dLevels of adiponectin in clinical subgroups at baseline
Covariate n
Total adiponectin (mg/L) HMW adiponectin (mg/L)
HMW-to-total
adiponectin ratio
Mean* (95% CI) P Mean* (95% CI) P Mean (95% CI) P
Sex ,0.001 ,0.001 ,0.001
Male 1,509 10.5 (10.2–0.72) 4.6 (4.4–4.8) 0.47 (0.46–0.48)
Female 2,293 14.6 (14.3–14.9) 7.5 (7.2–7.7) 0.54 (0.53–0.54)
Ethnicity ,0.001 ,0.001 ,0.001
Black 559 10.0 (9.5–10.42) 4.2 (3.9–4.6) 0.47 (0.45–0.48)
Nonblack 3,243 13.4 (13.1–13.6) 6.6 (6.4–6.7) 0.52 (0.51–0.52)
Field center 0.001 ,0.001 ,0.001
California 1,057 13.3 (12.8–13.7) 6.5 (6.2–6.8) 0.53 (0.53–0.54)
Maryland 795 13.2 (12.8–13.7) 6.7 (6.4–7.1) 0.51 (0.51–0.52)
North Carolina 940 12.3 (11.9–12.7) 5.6 (5.3–5.9) 0.49 (0.48–0.51)
Pennsylvania 1,010 12.4 (12.0–12.8) 5.9 (5.7–6.2) 0.50 (0.49–0.51)
Education 0.004 ,0.001 0.40
,High school 1,783 12.5 (12.2–12.8) 6.0 (5.8–6.2) 0.51 (0.50–0.52)
$High school 2,012 13.1 (12.8–13.4) 6.4 (6.2–6.6) 0.51 (0.51–0.52)
Smoking status ,0.001 ,0.001 ,0.001
Never 1,718 13.4 (13.1–13.7) 6.6 (6.3–6.8) 0.52 (0.51–0.52)
Former 1,641 12.2 (11.9–12.5) 5.7 (5.5–6.0) 0.50 (0.49–0.50)
Current 373 12.0 (11.4–12.6) 5.8 (5.4–6.2) 0.50 (0.49–0.52)
Alcohol consumption 0.01 0.04 0.24
None 1,982 12.8 (12.5–13.1) 6.2 (6.0–6.4) 0.51 (0.50–0.52)
,7 drinks/wk 1,298 12.5 (12.2–12.9) 5.9 (5.7–6.2) 0.50 (0.50–0.51)
$7 drinks/wk 515 13.5 (12.9–14.1) 6.6 (6.2–7.1) 0.52 (0.50–0.53)
Estrogen replacement
(in women) ,0.001 ,0.001 ,0.001
Yes 342 15.1 (14.3–15.8) 7.8 (7.3–8.4) 0.54 (0.52–0.55)
No 1,951 12.6 (12.4–12.8) 6.0 (5.9–6.2) 0.51 (0.50–0.51)
Self-reported health status 0.70 0.69 0.37
Poor/fair 661 12.9 (12.4–13.4) 6.2 (5.8–6.7) 0.52 (0.50–0.53)
Good/very good/excellent 3,140 12.8 (12.5–13.0) 6.1 (6.0–6.3) 0.51 (0.50–0.52)
Unintentional
weight loss .10 lb 0.002 0.003 0.002
Yes 210 14.4 (13.3–15.6) 7.3 (6.5–8.2) 0.51 (0.50–0.51)
No 3,237 12.6 (12.4–12.9) 6.0 (5.9–6.2) 0.54 (0.52–0.57)
Prevalent impaired
fasting glucose ,0.001 ,0.001 ,0.001
Yes 322 10.7 (10.1–11.3) 4.6 (4.2–5.1) 0.47 (0.46–0.49)
No 2,502 13.3 (13.0–13.5) 6.5 (6.3–6.6) 0.51 (0.51–0.52)
Prevalent CHD ,0.001 0.01 0.48
Yes 746 12.1 (11.6–12.5) 5.8 (5.4–6.1) 0.50 (0.49–0.51)
No 3,056 13.0 (12.7–13.2) 6.3 (6.1–6.4) 0.51 (0.50–0.51)
Prevalent heart failure 0.002 ,0.001 0.002
Yes 179 14.5 (13.4–15.8) 7.5 (6.7–8.42) 0.51 (0.50–0.51)
No 3,623 12.7 (12.5–12.9) 6.1 (5.9–6.3) 0.54 (0.52–0.56)
Prevalent atrial ﬁbrillation 0.08 0.03 0.03
Yes 99 14.1 (12.6–15.6) 7.3 (6.2–8.47) 0.54 (0.51–0.57)
No 3,685 12.8 (12.6–13.0) 6.1 (6.0–6.3) 0.51 (0.50–0.51)
Prevalent stroke 0.80 0.48 0.30
Yes 177 12.9 (11.9–14.0) 6.4 (5.7–7.18) 0.52 (0.50–0.54)
No 3,625 12.8 (12.6–13.0) 6.1 (6.0–6.3) 0.51 (0.50–0.51)
b-Blocker use ,0.001 ,0.001 0.04
Yes 275 10.6 (10.1–11.1) 4.6 (4.3–5.0) 0.48 (0.46–0.51)
No 3,014 13.1 (12.9–13.3) 6.4 (6.2–6.6) 0.51 (0.51–0.52)
ACE inhibitor or ARB 0.06 0.23 0.99
Yes 363 12.2 (11.6–12.8) 5.9 (5.4–6.4) 0.51 (0.50–0.52)
No 3,439 12.9 (12.6–13.1) 6.2 (6.0–6.4) 0.51 (0.50–0.52)
ARB, angiotensin receptor blocker; wk, week. *Geometric mean.
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Adiponectin and diabetes in older peoplewithincidentdiabeteswaslinearthroughout
its distribution (P =0 . 6 0f o rn o n l i n e a r i t y ) .
Consistent with the forms of these
associations, analyses of quartiles of total
and HMW adiponectin revealed graded
decreases in risk for quartiles 2 and 3
comparedwithquartile1,withquartiles3
and 4 exhibiting similar effect estimates
(Table 3). Signiﬁcantly reduced risks of
diabetes persisted after full adjustment
for confounding variables (model 2),
with quartiles 3 and 4 showing ;60%
lower risk than the referent quartile.
These risk estimates were virtually identi-
cal for total and HMW adiponectin.
When putative mediators of the associa-
tionwereincludedinthesemultivariable
models, and notably baseline HOMA-IR
(or fasting glucose), the reduced risks
observed for the quartile 3 versus quar-
tile 1 comparisons of total and HMW
adiponectin remained signiﬁcant, but
those for quartile 4 versus quartile 1 be-
came nonsigniﬁcant.
The associations of continuous lev-
els of total and HMW adiponectin with
incident diabetes, stratiﬁed by their cor-
responding inﬂection points, are also
presented in Table 3. There were signif-
icant and comparable inverse associa-
tions for total adiponectin and HMW
adiponectinwithoutcomeuptoconcen-
trations of 20 and 10 mg/L, respectively.
These associations were attenuated but
remained statistically signiﬁcant after
adjustment for mediators, characterized
by risk reductions of 25% and 35% per
SD increase for total adiponectin and
HMW adiponectin, respectively, with
overlapping 95% CIs (Table 3). By con-
trast, no signiﬁcant associations with
outcome were observed for further in-
creases of total and HMW adiponectin
beyondlevelsof20and10mg/L,respec-
tively, with or without adjustment for
confounders or mediators.
As reported in Table 3, the ratio of
HMW to total adiponectin showed a sig-
niﬁcant inverse association with outcome
as well, which, in keeping with lack of
departure from linearity in splines analy-
ses, did not exhibit the same apparent
leveling off of risk reductions for the
upper quartiles. Although signiﬁcantly
lowerriskswereobserved forupperquar-
tiles compared with quartile 1 in models
fully adjusted for confounders, these sig-
niﬁcant associationsdisappeared after ad-
justment for mediators. Likewise, the
analysisofthe HMW-to-total adiponectin
ratio as a continuous variable showed a
signiﬁcant 20% lower risk of incident
Figure 1dSpline regression graphs depict the associations of continuous levels of total
adiponectin(A),HMWadiponectin(B),andtheHMW-to-totaladiponectinratio(C)withincident
diabetes.The95%CIsarepresentedinlightgray.Allmodelsareadjustedforage,sex,race,income,
smoking, alcohol, eGFR, prevalent heart failure, prevalent atrial ﬁbrillation, prevalent CHD,
b-blocker use, health status, and BMI.
care.diabetesjournals.org DIABETES CARE, VOLUME 35, FEBRUARY 2012 419
Kizer and AssociatesdiabetesassociatedwitheverySDincrease
in the ratio after complete adjustment for
confounders, but the relation was no lon-
ger signiﬁcant with additional inclusion
of mediators.
In the foregoing analyses, there were
no signiﬁcant overall interactions between
total and HMW adiponectin with dichot-
omous age (P = 0.82 and 0.71, respec-
tively), sex (P = 0.15 and 0.059), race
(P = 0.51 and 0.45), or BMI (P =0 . 5 1
and 0.41). Findings were similar for con-
tinuous age and BMI. Nor was there evi-
dence of signiﬁcant effect-modiﬁcation by
these covariates above or below the corre-
sponding adiponectin cut points. There
were, however, signiﬁcant interactions
with binary HOMA-IR for total and
HMW adiponectin below (P = 0.010 and
0.030) but not above (P = 0.17 and 0.37)
their respective cut points, such that effect
modiﬁcation was signiﬁcant overall for to-
tal (P = 0.035) but not HMW adiponectin
(P = 0.098). For HOMA-IR ,3.21 (75th
percentile), total and HMW adiponectin
were signiﬁcantly inversely related to in-
cident diabetes (adjusted [model 2] HR
per SD 0.44 [95% CI 0.32–0.62], and
0.40 [0.27–0.59], respectively), but these
associations were blunted for HOMA-IR
$3.21 (0.81 [0.57–1.14] and 0.73 [0.48–
1.10]). The signiﬁcant associations within
the insulin-sensitive stratum (HOMA-IR
,3.21) remained minimally altered with
additional adjustment for HOMA-IR
(0.50 [0.36–0.70] for total adiponectin;
0.44 [0.29–0.66] for HMW adiponectin).
A similar pattern of effect modiﬁcation
waspresentwhenHOMA-IRwasmodeled
continuously.Therewereagainsigniﬁcant
interactions for total and HMW adiponec-
tin below their cut points (P = 0.013 and
0.030, respectively), but not above (P =
0.12 and 0.30, respectively), with the
overall interaction achieving signiﬁ-
cance for total (P = 0.039) but not HMW
adiponectin (P = 0.20).
Last, ﬁndings were not materially
changed when only incident events after
the ﬁrst 5 years of follow-up were consid-
ered, when diabetes diagnosis was based
solely on medications, or after exclusion of
participants with involuntary weight loss
andprevalentCHD,heartfailure,andatrial
ﬁbrillation.
CONCLUSIONSdToourknowledge,
this is the largest prospective study to
evaluate the relationship of adiponectin
with new-onset diabetes in older people,
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Adiponectin and diabetes in older peopleinvestigation yields several novel ﬁndings
with regard to the adiponectin–diabetes
association in older adults. First among
them is a departure from linearity in the
relationships of total and HMW adipo-
nectin with incident diabetes. As deter-
mined by the use of linear splines, there
wasastronginverseassociationbetween
total and HMW adiponectin levels and
diabetes up to concentrations of approxi-
mately 20 and 10 mg/L, respectively,
above which the risk associated with fur-
ther increases plateaued.
A departure from linearity in the
association between adiponectin and di-
abetes has only been reported to date in a
cohort of middle-aged women, wherein
there was a stronger decrease in risk for
the lower range of the adipokine’s distri-
butionthanforthehigherrange(12).Un-
like our ﬁndings, the inverse association
continued to be evident at the higher end
of adiponectin concentrations, even if in
attenuated form, but total and HMW adi-
ponectin concentrations in that study
were lower than those observed in our
older cohort, as were their corresponding
inﬂection points (12). Nevertheless, be-
cause the numbers of incident diabetes
cases .20 mg/L of total adiponectin and
.10 mg/L of HMW adiponectin in our
study were modest (n =3 0a n dn = 40,
respectively), the relationships in the up-
per range lack precision for adequate
comparison. Moreover, in the absence of
an adiponectin measurement standard,
ﬁrm conclusions about differences in ab-
solute values of adiponectin concentra-
tions and the cut points observed in the
two studies are not possible.
Still, the leveling off of risk observed
here for the higher range of total and
HMW adiponectin concentrations has
important implications. Because prior
studies have not identiﬁed a plateauing
of the association at the higher end of
values (9), but have modeled it instead as
linear throughout the distribution of the
adipokine,effectestimatesforcontinuous
associations may have been underestima-
ted. In fact, when expressed per log-mg/L
increase, the relative risk for total adipo-
nectin levels ,20 mg/L observed here
(0.41 [95% CI 0.31–0.55]) is substan-
tially lower than that reported for older
cohorts (mean age .60 years) in the
meta-analysis (0.77 [0.70–0.84]) (9), al-
though the caveat about lack of measure-
ment standardization across cohorts
applies.
Furthermore, the shape of the asso-
ciation deﬁned by the present analyses
may shed light on the adiponectin “para-
dox” (26). This refers to the conundrum
that despite the insulin-sensitizing and
antiatherogenic properties demonstrated
for adiponectin in laboratory studies, and
the protective relationship with cardio-
vascular events documented for total adi-
ponectin in healthy younger populations,
the association with cardiovascular out-
comes and all-cause mortality in older
or higher-risk populations has instead
been adverse.
Theplateauingoftheassociation.20
mg/L observed here is consistent with a
recently reported U-shaped relation with
all-cause mortality in CHS survivors en-
rolledinthefollow-upCHSAllStarsstudy,
whoseadiponectinlevelsweremeasuredin
1996–1997 and again 9 years later (25). In
theCHSAllStarsStudy,aninﬂectionpoint
atapproximatelythesamevalueof20mg/L
was likewise manifest, even though sam-
ples were collected 13 years after the pres-
ent ones (25). The current results could
provide a plausible framework for under-
standing the mortality ﬁnding, indicating
as they do that although higher adiponec-
tin levels have favorable glycometabolic
consequences within the lower range of
values, oncelevelsexceedthe 80th percen-
tile,furtherincreasesinadiponectinappear
to afford no additional glycometabolic
beneﬁts. If levels at the higher range re-
ﬂect adiponectin increases occurring in
response to homeostatic dysregulation
or aging-related disease processes (e.g.,
vascular disease, inﬂammation) (25),
they would tend to be associated with
the unfavorable glycometabolic outlook
and otherwise adverse prognosis that ac-
companies such processes. This might
explain the offset of further gains with
regard to diabetes risk at the high end
of adiponectin values, and with it, the
heightened risk of all-cause mortality
documented previously.
Another notable ﬁnding concerns
the relative associations of total and
HMW adiponectinwith incident diabetes,
evaluated concurrently for the ﬁrst time
in an older population. Although HMW
adiponectin showed slightly stronger ef-
fect estimates than total adiponectin, the
relative risks were not signiﬁcantly dif-
ferent. And although the difference was
sufﬁcient to confer a linear inverse asso-
ciationfortheHMW-to-totaladiponectin
ratio that held throughout its distribu-
tion, the relationship ceased to be signiﬁ-
cant once putative mediators were taken
intoaccount.Takentogether,theseﬁndings
argue against a substantial advantage to
measuring HMW adiponectin over, or in
addition to, total adiponectin for assess-
ment of glycometabolic risk.
Our analyses did not document sig-
niﬁcant effect-measure modiﬁcation by
sex (27) or BMI (10), as suggested in ear-
lier studies. They did, however, show evi-
dence of interaction by a proxy measure of
insulin resistance, HOMA-IR, wherein the
strong inverse associations documented
for the lower range of the adiponectin
measures held for HOMA-IR values ,3.21
but were blunted at higher values. Interest-
ingly, this ﬁnding is contrary to those of a
previous report, in which inverse associa-
tions between total adiponectin and inci-
dent diabetes were documented only
among insulin-resistant (HOMA-IR $75th
percentile) participants in two population-
based cohorts, but not in their insulin-
sensitive counterparts (28). The basis for
the different ﬁndings is uncertain, although
the numbers of diabetes cases for explor-
ing the nature of the relationship were mod-
est in each of the two cohorts, a signiﬁcant
interaction by HOMA-IR was detected only
in one, and the study populations were
younger than the one studied here (28).
Nevertheless, our ﬁnding has relevance for
an important unresolved question in the
ﬁeld, namely, whether the association of hy-
poadiponectinemiawithincidentdiabetesin
humans results from insufﬁcient insulin-
sensitizing (or pancreatic b-cell enhancing)
effects otherwise exerted directly by the
adipokine or instead reﬂects the sup-
pressive effects of hyperinsulinemia on
adiponectin production by adipocytes
(29). That the inverse associations detailed
herepersistedafteradjustmentforHOMA-
IR, and were stronger in insulin-sensitive
participants at baseline, supports a role
for adiponectin that is independent of hy-
perinsulinemia.Moredeﬁnitiveassessment
of the complex interplay between insulin
and adiponectin, however, will require an
approach predicated on serial measure-
ments of insulin and adiponectin. Addi-
tional work is necessary to elucidate the
pathophysiologic pathways involved, and
whetherdevelopmentoftherapiesthatspe-
ciﬁcally raise adiponectin levels could re-
sult in glycometabolic and cardiovascular
health beneﬁts.
Severallimitationsmeritconsideration.
Because adiponectin measurements were
obtainableonlyinahealthiersubsetofCHS
participantsin1992–1993,thepresentﬁnd-
ings may not apply to more disease-prone
older cohorts. Diabetes ascertainment was
based on medication inventory throughout
follow-up, but regular determinations of
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Kizer and Associatesfasting blood glucose were only possible
during the initial 6 years, with a ﬁnal mea-
surement 13 years later in a subgroup.
There was no evidence of differential asso-
ciations, however, when the outcome was
limited to treated diabetes. In addition, we
lacked2-hglucosetolerancetesting,which
may have resulted in misclassiﬁcation of
prevalent and incident diabetes in our co-
hort. Laboratory testing in this cohort also
did not include direct measures of insulin
sensitivity or insulin secretion, which
would have permitted more accurate, de-
tailedassessmentoftherelationsofinterest.
Last,asnoted,ourstudyhadlimitedpower
to deﬁne the precise shape of the relation-
ship of adiponectin with diabetes in the
upperrange.Largerstudieswillberequired
tobettercharacterizetherelationshipatthe
higher end and to explore the underlying
basis for its apparent attenuation.
In conclusion, in this large older co-
hort, total and HMW adiponectin exhib-
ited a nonlinear association with incident
diabetes, wherein levels up to 20 and 10
mg/L, respectively, showed strong inverse
associations that were independent of
potential confounders and even proposed
intermediates, but additional increases
above these levels conferred no further
detectable lowering in incident diabetes
risk. The inverse associations within the
lowerrangeweremorepronouncedamong
insulin-sensitive than insulin-resistant
individuals. These data do not demon-
strate meaningful superiority of HMW
over total adiponectin for assessment of
diabetes risk and argue against baseline
hyperinsulinemiaastheunderlyingbasis
for the observed associations.
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